Docetaxel: New Indication for Prostate Cancer - A Few More Weeks

    February 2006 in “ PubMed ”
    TLDR Docetaxel slightly extends prostate cancer survival but has significant side effects and high cost.
    Docetaxel was approved in Europe for treating hormone-resistant metastatic prostate cancer and demonstrated a modest survival benefit. In a trial with 1006 patients, docetaxel combined with prednisone extended median survival by about 2.5 months compared to mitoxantrone-prednisone. Another trial with 674 patients showed docetaxel with estramustine was more effective than mitoxantrone-prednisone, extending survival by 1.9 months. Despite these benefits, docetaxel's adverse effects, including hair loss and severe reactions in 25% of patients, and its high cost, limited its overall advantage.
    Discuss this study in the Community →

    Related Community Posts Join

    0 / 0 results
    — no results

    Similar Research

    5 / 345 results
      Prostate Cancer Update: 2007

      research Prostate Cancer Update: 2007

      6 citations , May 2008 in “Current Opinion in Oncology”
      2007 research improved understanding of prostate cancer risk, diagnosis, and treatment, but also showed the need for personalized treatment and further study on certain therapies' risks.
      Prostate Cancer Update: 2007

      research Prostate Cancer Update: 2007

      August 2008 in “Current Opinion in Internal Medicine”
      In 2007, prostate cancer research improved understanding of risk, diagnosis, and treatment, but also showed heart risks with certain therapies and the need for personalized care.
      Redefining Hormone Resistance in Prostate Cancer

      research Redefining Hormone Resistance in Prostate Cancer

      38 citations , December 2009 in “Therapeutic Advances in Medical Oncology”
      The conclusion suggests that prostate cancer should be classified by castration status and that new therapies targeting androgen receptor signaling show promise.